The Need for Multiple Doses of 400 mg Ketoconazole as a Precipitant Inhibitor of a CYP3A Substrate in an In Vivo Drug-Drug Interaction Study

被引：12
|
作者：
Oo, Charles [1 ]
Chen, Chi [1 ]
机构：
[1] Asubio Pharmaceut Inc, Rochelle Pk, NJ 07662 USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2009年 / 49卷 / 03期
关键词：
PHARMACOKINETICS; PREDICTION;
D O I：
10.1177/0091270008325931
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：368 / 369
页数：2
相关论文
共 33 条
  • [31] Drug-drug interaction between diltiazem and tacrolimus in relation to CYP3A5 genotype status in Chinese pediatric patients with nephrotic range proteinuria: a retrospective study
    Yang, Qiaoling
    Wang, Yan
    Wang, Xuebin
    Wang, Ping
    Tan, Boyu
    Li, Yijun
    Sun, Huajun
    Huang, Wenyan
    Liu, Hongxia
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [32] Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study
    Lang, Jennifer
    Vincent, Ludwig
    Chenel, Marylore
    Ogungbenro, Kayode
    Galetin, Aleksandra
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (06) : 1618 - 1630
  • [33] Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug-Drug Interaction Study
    Moreno, Irene
    Hernandez, Tatiana
    Calvo, Emiliano
    Fudio, Salvador
    Kahatt, Carmen
    Fernandez, Cristian
    Iglesias, Jorge Luis
    Corral, Gema
    Perez-Ramos, Laura
    Montilla, Lola
    Zeaiter, Ali
    Lubomirov, Rubin
    PHARMACEUTICALS, 2024, 17 (02)
1234